



FINAL REPORT

VIRUS FILTRATION EFFICIENCY TEST (VFE)
AT AN INCREASED CHALLENGE LEVEL

PROCEDURE NO. SOP/ARO/018F.1

LABORATORY NO. 308501.1 AMENDED

PREPARED FOR:

JOSE ALBERTO HERNANDEZ
MEDICAL RESEARCH & DEVELOPMENT
PASEO DE LAS ACACIAS 17
28820 COSLADA-MADRID
SPAIN

SUBMITTED BY:

NELSON LABORATORIES, INC.
6280 SOUTH REDWOOD ROAD
SALT LAKE CITY, UT 84123-6600
801-963-2600



A handwritten signature in black ink, appearing to be "M. J. J.", located in the bottom right corner of the page.



VIRUS FILTRATION EFFICIENCY TEST (VFE)
AT AN INCREASED CHALLENGE LEVEL

LABORATORY NUMBER:	308501.1 Amended
PROCEDURE NUMBER:	SOP/ARO/018F.1
SAMPLE SOURCE:	Medical Research & Development
SAMPLE IDENTIFICATION:	Refer to Table 1
DEVIATIONS:	None
DATA ARCHIVE LOCATION:	Sequentially by lab number
SAMPLE RECEIVED DATE:	26 Oct 2005
LAB PHASE START DATE:	02 Nov 2005
LAB PHASE COMPLETION DATE:	04 Nov 2005
REPORT ISSUE DATE:	07 Nov 2005
STUDY COMPLETION DATE:	11 Nov 2005
AMENDED REPORT ISSUE DATE:	14 Nov 2005

AMENDMENT JUSTIFICATION:

At the request of the sponsor the report was changed from short format to long format.

INTRODUCTION:

This report describes the procedure and results of the virus filtration efficiency (VFE) at increased challenge level testing. This procedure was performed to determine the filtration efficiency of the test materials using a ratio of the challenge to effluent to determine percent efficiency. This procedure allowed a reproducible aerosol challenge to be delivered to each of the test materials. This test procedure was modified from Nelson Laboratories, Inc., standard VFE test and employed a more severe challenge than would be expected in normal use.

JUSTIFICATION:

This VFE test provides a number of advantages over other filtration efficiency tests. The use of all glass impingers (AGIs) in the collection process allowed a high concentration of challenge to be delivered to each test material. The aerosol challenge particle size can be tightly controlled by monitoring the airflow and challenge flow through the nebulizer. The aerosol particles can be sized using a six-stage viable particle Andersen sampler.

The ϕ X174 bacteriophage has a diameter of 27 nm (0.027 μ m) and, therefore, provides a severe challenge to the test filter.

ACCEPTANCE CRITERIA:

The mean particle size (MPS) of the challenge aerosol must be maintained at $3.0 \pm 0.3 \mu$ m.

The average percent virus filtration efficiency (%VFE) for the reference material must be within the upper and lower control limits established for the VFE test.

CHALLENGE PROCEDURE:

The stock bacteriophage ϕ X174 was prepared by inoculation of ϕ X174 into a log phase culture of *E. coli* C. The culture was shaken at $37 \pm 2^\circ\text{C}$ until bacterial turbidity cleared. The virus stock was centrifuged to remove large cellular debris and then filtered through a 0.2 μ m membrane filter to remove remaining host cell debris. The stock culture was stored at 2-8°C.

The challenge suspension was pumped through a 'Chicago' nebulizer using a peristaltic pump at a controlled flow rate and fixed air pressure. The constant challenge delivery formed aerosol droplets of defined size. The challenge level was adjusted to provide a consistent challenge of greater than 10^6 plaque forming units (PFU) per test sample.

The aerosol droplets were generated in a glass aerosol chamber and drawn through the sample holder and into all AGIs in parallel. Each AGI contained 30 mL aliquots of sterile peptone water (PEPW) to collect the aerosol droplets. The aerosol challenge flow rate was maintained at 30 Liters per minute (Lpm).

The challenge was delivered for a 1 minute interval and sampling through the AGIs was conducted for 2 minutes to clear the aerosol chamber. Control runs (no media in sample holder) were performed after every 5-7 test samples to determine the number of viable particles being generated in the challenge aerosol.

The AGI fluid was assayed using standard plaque assay techniques. All plates were incubated at $37 \pm 2^\circ\text{C}$ for 12-24 hours.

STATEMENT OF UNCERTAINTY:

If applicable, the statement of uncertainty is available to sponsors upon request.

RESULTS:

The filtration efficiencies were calculated using the following equation:

$$\%VFE = \frac{\text{Plaques without filter} - \text{Plaques with filter}}{\text{Plaques without filter (Control)}} \times 100$$

The MPS of the challenge aerosol was determined using a six-stage Andersen sampler. The challenge level, MPS, and filtration efficiencies of the samples are summarized in Table 1.

JDA

Technical Reviewer

Stacey Cushing

Stacey Cushing, B.S.
Study Director

18 Nov 2005

Amended Report Date

djo

TABLE 1. VFE Results
Lot #01/2005

SAMPLE IDENTIFICATION	TOTAL PFU RECOVERED	FILTRATION EFFICIENCY
Neumofilt #1	<1*	>99.999909%
Neumofilt #2	<1*	>99.999909%
Neumofilt #3	<1*	>99.999909%
Neumofilt #4	<1*	>99.999909%
Neumofilt #5	<1*	>99.999909%

Challenge Level (PFU): 1.1×10^6 PFU

Mean Particle Size (MPS): 2.9 μ m

* There were no detected plaques on any of the assay plates for this sample.



Medical Research & Development
Lab Number 308501.1 Amended

VFE at an Increased Challenge Level
Page 6 of 6

All reports and letters issued by Nelson Laboratories, Inc. are for the exclusive use of the sponsor to whom they are addressed. Reports may not be reproduced except in their entirety. No quotations from reports or use of the corporate name is permitted except as expressly authorized by Nelson Laboratories, Inc. in writing. The significance of any data is subject to the adequacy and representative character of the samples tendered for testing. Nelson Laboratories, Inc. warrants that all tests are performed in accordance with established laboratory procedures and standards. Nelson Laboratories, Inc. makes no other warranties of any kind, express or implied. Nelson Laboratories, Inc. expressly states that it makes no representation or warranty regarding the adequacy of the samples tendered for testing for any specific use of application, that determination being the sole responsibility of the sponsor. Nelson Laboratories' liability for any loss or damage resulting from its actions or failure to act shall not exceed the cost of tests performed, and it shall not be liable for any incidental or consequential damages.



FINAL REPORT

BACTERIAL FILTRATION EFFICIENCY TEST (BFE)
AT AN INCREASED CHALLENGE LEVEL

PROCEDURE NO. SOP/ARO/017E.1

LABORATORY NO. 308500.1 AMENDED

PREPARED FOR:

JOSE ALBERTO HERNANDEZ
MEDICAL RESEARCH & DEVELOPMENT
PASEO DE LAS ACACIAS 17
28820 COSLADA-MADRID
SPAIN

SUBMITTED BY:

NELSON LABORATORIES, INC.
6280 SOUTH REDWOOD ROAD
SALT LAKE CITY, UT 84123-6600
801-963-2600



A handwritten signature in black ink, appearing to be "myjo" or similar, located in the bottom right corner of the page.



BACTERIAL FILTRATION EFFICIENCY TEST (BFE)
AT AN INCREASED CHALLENGE LEVEL

LABORATORY NUMBER:	308500.1 Amended
PROCEDURE NUMBER:	SOP/ARO/017E.1
SAMPLE SOURCE:	Medical Research & Development
SAMPLE IDENTIFICATION:	Refer to Table 1
DEVIATIONS:	None
DATA ARCHIVE LOCATION:	Sequentially by lab number
SAMPLE RECEIVED DATE:	26 Oct 2005
LAB PHASE START DATE:	01 Nov 2005
LAB PHASE COMPLETION DATE:	04 Nov 2005
REPORT ISSUE DATE:	07 Nov 2005
STUDY COMPLETION DATE:	11 Nov 2005
AMENDED REPORT ISSUE DATE:	14 Nov 2005

AMENDMENT JUSTIFICATION:

At the request of the sponsor the report was changed from short format to long format.

ACCEPTANCE CRITERIA:

The mean particle size of the challenge aerosol must be maintained at $3.0 \pm 0.3 \mu\text{m}$.

The average percent bacterial filtration efficiency (%BFE) for the reference material must be within the upper and lower control limits established for the bacterial filtration efficiency (BFE) test.

INTRODUCTION:

This report describes the procedure and results of the BFE at increased challenge level testing. This procedure was performed to determine the filtration efficiency of the test materials using a ratio of the challenge to effluent to determine percent efficiency. This procedure allowed a reproducible aerosol challenge to be delivered to each of the test materials. This test procedure employed a challenge level of greater than 10^6 colony forming units (CFU) per test sample, providing a higher challenge than would be expected in normal use.

RESULTS:

The filtration efficiencies were calculated using the following equation:

$$\% \text{ BFE} = \frac{C - T}{C} \times 100$$

Where: C = Average of control values.
T = Count total for test material.

The mean particle size (MPS) of the challenge aerosol was determined using a six-stage Andersen sampler. The challenge level, MPS, and filtration efficiencies of the samples are summarized in Table 1.

J. DA

Technical Reviewer

Stacey Cushing
Stacey Cushing, B.S.
Study Director

18 Nov 2005
Amended Report Date

TABLE 1. BFE Results
Lot #01/2005

SAMPLE IDENTIFICATION	TOTAL CFU RECOVERED	FILTRATION EFFICIENCY
Neumofilt #1	<1*	>99.999980%
Neumofilt #2	<1*	>99.999980%
Neumofilt #3	<1*	>99.999980%
Neumofilt #4	<1*	>99.999980%
Neumofilt #5	<1*	>99.999980%

Challenge Level: 5.0×10^6 CFU

Mean Particle Size (MPS): 3.2 μ m

* There were no detected colonies on any of the assay plates for this sample.

All reports and letters issued by Nelson Laboratories, Inc. are for the exclusive use of the sponsor to whom they are addressed. Reports may not be reproduced except in their entirety. No quotations from reports or use of the corporate name is permitted except as expressly authorized by Nelson Laboratories, Inc. in writing. The significance of any data is subject to the adequacy and representative character of the samples tendered for testing. Nelson Laboratories, Inc. warrants that all tests are performed in accordance with established laboratory procedures and standards. Nelson Laboratories, Inc. makes no other warranties of any kind, express or implied. Nelson Laboratories, Inc. expressly states that it makes no representation or warranty regarding the adequacy of the samples tendered for testing for any specific use of application, that determination being the sole responsibility of the sponsor. Nelson Laboratories' liability for any loss or damage resulting from its actions or failure to act shall not exceed the cost of tests performed, and it shall not be liable for any incidental or consequential damages.